Related Experiment Videos
Update of hormonal treatment in cancer of the prostate
1Department of Urology, University Hospital Nijmegen, The Netherlands.
Abstract:
Prostate carcinomas are heterogeneous tumors composed of hormone sensitive and hormone insensitive cells. Although all androgens have an effect on prostatic cells, it is believed that dihydrotestosterone (DHT) is the active metabolite primarily utilized by prostatic cancer cells for growth and division. Hormonal therapies are therefore designed to lower tissue levels of DHT or prevent its binding to receptors on prostatic cancer cells. The Veterans Administration Cooperative studies in the 1960s and 1970s laid the groundwork for the use and timing of hormonal therapy. Until recently orchiectomy and estrogens were the two main alternatives, but new compounds such as luteinizing hormone releasing hormone analogs and antiandrogens have shown to be as effective and less toxic than estrogens. Today, important controversies concerning the selection of the best primary treatment and the timing of initiating the hormonal therapy still exist. Second line hormonal strategies are used, but they still have to prove their impact on overall survival.
Insights
Prostate cancer treatment involves hormonal therapies targeting dihydrotestosterone (DHT). While effective, controversies remain regarding optimal treatment selection and timing for improved survival outcomes.
Area of Science:
- Oncology
- Endocrinology
- Urology
Background:
- Prostate carcinomas exhibit heterogeneity, including hormone-sensitive and insensitive cells.
- Dihydrotestosterone (DHT) is the primary androgen metabolite driving prostate cancer cell growth.
- Hormonal therapies aim to reduce DHT levels or block its receptor binding.
Purpose of the Study:
- To review the historical context and evolution of prostate cancer hormonal therapies.
- To discuss current controversies in primary treatment selection and therapy initiation timing.
- To evaluate the role and efficacy of second-line hormonal strategies.
Main Methods:
- Review of historical Veterans Administration Cooperative studies.
- Analysis of established and novel hormonal agents (orchiectomy, estrogens, LHRH analogs, antiandrogens).
- Discussion of clinical controversies and future research directions.
Main Results:
- Hormonal therapy has been a cornerstone of prostate cancer management since the mid-20th century.
- Newer agents like LHRH analogs and antiandrogens offer comparable efficacy with reduced toxicity compared to older treatments.
- Significant debates persist regarding the optimal primary treatment and the ideal timing for initiating hormonal therapy.
Conclusions:
- Hormonal therapy remains critical for managing prostate cancer, targeting the androgen pathway.
- Ongoing research and clinical trials are essential to resolve treatment selection and timing controversies.
- The impact of second-line hormonal therapies on overall survival requires further validation.